Proceedings of the National Academy of SciencesBioinformaticsPeer-reviewed journal article
Machine learning classification can reduce false positives in structure-based virtual screening
Abstract
With the recent explosion in the size of libraries available for screening, virtual screening is positioned to assume a more prominent role in early drug discoverys search for active chemical matter. Modern virtual screening methods are still, however, plagued with high false positive rates: typically, only about 12% of the top-scoring compounds actually show activity when tested in biochemical assays. We argue that most scoring functions used for this task have been developed with insufficient thoughtfulness into the datasets on which they are trained and tested, leading to overly simplistic models and/or overtraining. These problems are compounded in the literature because none of the studies reporting new scoring methods have validated their model prospectively within the same study. Here, we report a new strategy for building a training dataset (D-COID) that aims to generate highly-compelling decoy complexes that are individually matched to available active complexes. Using this dataset, we train a general-purpose classifier for virtual screening (vScreenML) that is built on the XGBoost framework of gradient-boosted decision trees. In retrospective benchmarks, our new classifier shows outstanding performance relative to other scoring functions. We additionally evaluate the classifier in a prospective context, by screening for new acetylcholinesterase inhibitors. Remarkably, we find that nearly all compounds selected by vScreenML show detectable activity at 50 {micro}M, with 10 of 23 providing greater than 50% inhibition at this concentration. Without any medicinal chemistry optimization, the most potent hit from this initial screen has an IC50 of 280 nM, corresponding to a Ki value of 173 nM. These results support using the D-COID strategy for training classifiers in other computational biology tasks, and for vScreenML in virtual screening campaigns against other protein targets. Both D-COID and vScreenML are freely distributed to facilitate such efforts.
- assay: protein structure
- research focus: drug response / drug discovery
- research focus: benchmarking
- research focus: software / tool
- approach: machine learning (classical)
- Citations
- 225
- FWCI
- 13.63
- Field percentile
- top 1%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- vScreenML v2.0: Improved Machine Learning Classification for Reducing False Positives in Structure-Based Virtual Screening
Grigorii V. Andrianov, Emeline Haroldsen, John Karanicolas·International Journal of Molecular SciencesPeer-reviewed·Nov 18, 2024
- Overcoming the accuracy-generalization tradeoff in docking and scoring for prospective virtual screening
Garik Petrosyan, Vahagn Altunyan, … Garegin A. Papoian·bioRxiv·Aug 3, 2026
- The impact of compound library size on the performance of scoring functions for structure-based virtual screening
Louison Fresnais, Pedro J. Ballester·Briefings in BioinformaticsPeer-reviewed·Apr 29, 2020
- A Machine Learning-Enabled Pipeline for Large-Scale Virtual Drug Screening
A. Gupta, H.-X. Zhou·bioRxiv·Jun 20, 2021
- Deep Learning for Virtual Screening: Five Reasons to Use ROC Cost Functions
V. Golkov, A. Becker, … D. Cremers·bioRxiv·Jun 25, 2020
- Establishing the foundations for a data-centric AI approach for virtual drug screening through a systematic assessment of the properties of chemical data
Allen Chong, Ser-Xian Phua, … Wilson Wen Bin Goh·bioRxiv·Mar 28, 2024